"Last week, GlaxoSmithKline agreed to plead guilty to criminal charges and pay a total of $3 billion to resolve allegations pertaining to several other drugs, the illegal marketing of them, and the obscuring of clinical data from the FDA. "Today's multibillion dollar settlement is unprecedented in both size and scope," Deputy Attorney General James M. Cole said in a press conference.
The investigation unearthed at least a decade's worth of physician kickbacks, fraudulent marketing, and various other kinds of legal (and ethical) boundaries breached, though this kind of behavior seems par for the course across the industry: Last year, Johnson & Johnson, pleading guilty to bribing foreign doctors, agreed to fork up $70 million in fines. As of April, Bristol-Myers Squibb has been subpoenaed by the SEC (likely for something similar), and Merck, Eli Lilly, GlaxoSmithKline, and AstraZeneca have said they are also cooperating with investigations, according to the New York Times."
...
No comments:
Post a Comment